Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions

The development of inhibitors of immune checkpoints has revolutionized the treatment for a subset of patients with advanced nonsmall cell lung cancer (NSCLC), resulting in promising clinical outcomes and durable responses. Pembrolizumab, a humanized anti-programmed cell death-1 (PD-1) antibody, has been approved as a first-line treatment for patients with advanced NSCLC with PD-L1 expression of ≥50% and as a second-line treatment for PD-L1 expression of ≥1%. Pembrolizumab in combination with standard chemotherapy has shown better clinical outcomes than chemotherapy as a first-line therapy in patients with advanced NSCLC without targetable mutations, regardless of PD-L1 expression. In this review, we summarized the current indications of pembrolizumab for NSCLC, briefly described immune-relevant pneumonitis and discussed potential biomarkers to predict clinical efficacy.

• Publication year

  2019

• Venue

  Journal of Cancer Research and Therapeutics

• Publication date

  2019-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4103/jcrt.JCRT_903_18PMID 31436226
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

  2018cited by this paper
• Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.

  2017cited by this paper
• The next generation of immunotherapy: keeping lung cancer in check

  2017cited by this paper
• Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities

  2016cited by this paper
• Interstitial lung diseases in the hospitalized patient

  2015cited by this paper
• Tumor immune microenvironment characterization and response to anti-PD-1 therapy

  2015cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper

• Clinical features and prognosis analysis of stage III/IV patients with lung cancer after treatment with toripalimab: A real-world retrospective.

  2024cites this paper
• Cost-effectiveness analysis of pembrolizumab with chemotherapy for metastatic nonsquamous non-small cell lung cancer in Taiwan

  2024cites this paper
• Efficiency and Future Significance of CTLA-4 and PD-1 Checkpoints Blockade Immunotherapy

  2023cites this paper
• Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics

  2023cites this paper
• Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC

  2023cites this paper
• Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma

  2023cites this paper
• Peptide G-Protein-Coupled Receptors and ErbB Receptor Tyrosine Kinases in Cancer

  2023cites this paper
• Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers

  2023cites this paper
• Aggregation-Induced Emission (AIE), Life and Health

  2023cites this paper
• Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma

  2023cites this paper
• Immunochemotherapy includes pembrolizumab for stage IIIB lung squamous cell carcinoma: a case report

  2022cites this paper
• Imaging of Activated T Cells

  2022cites this paper
• Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing

  2022cites this paper
• Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer

  2022cites this paper
• Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status

  2022cites this paper
• Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities

  2022cites this paper
• Overexpression of 14-3-3ζ primes disease recurrence, metastasis and resistance to chemotherapy by inducing epithelial-mesenchymal transition in NSCLC

  2022cites this paper
• Single-cell analysis of peripheral CD8^+ T cell responses in patients receiving checkpoint blockade immunotherapy for cancer

  2022cites this paper
• A historic opportunity for universal health coverage in India.

  2022cites this paper
• Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study

  2022cites this paper
• Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052/484 spheroids

  2021cites this paper
• Recent advances in primary resistance mechanisms against immune checkpoint inhibitors

  2021cites this paper
• Mutational burden and immune recognition of gliomas

  2021cites this paper
• Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report

  2021cites this paper
• Novel strategies for immuno-oncology breakthroughs with cell therapy

  2021cites this paper
• Oligometastatic non-small cell lung cancer: Current management

  2021cites this paper
• Immunotherapy in rare ovarian cancer

  2021cites this paper
• Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC

  2021cites this paper
• A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab

  2021cites this paper
• Cancer microenvironment and genomics: evolution in process

  2021cites this paper
• Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials

  2021cites this paper
• A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer

  2021cites this paper
• The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors

  2021cites this paper
• Systemischer Effekt einer lokalen Strahlentherapie: erste klinische Evidenz

  2021influential citation
• POU2F1 induces the immune escape in lung cancer by up-regulating PD-L1.

  2021cites this paper
• Nacimiento de la quimioterapia

  2021cites this paper
• PD-L1 as a biomarker of response to immune-checkpoint inhibitors

  2021cites this paper
• Anticancer Natural Products Targeting Immune Checkpoint Protein Network.

  2021cites this paper
• Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

  2021cites this paper
• Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review

  2020cites this paper
• The G Protein–Coupled Receptor PAC1 Regulates Transactivation of the Receptor Tyrosine Kinase HER3

  2020cites this paper
• Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I

  2020cites this paper
• Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

  2020cites this paper
• Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors

  2020cites this paper
• The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models

  2020cites this paper
• Radiological Monitoring of Modern Immunotherapy: A Novel Challenge for Interdisciplinary Patient Care Radiologisches Monitoring von modernen Immuntherapien: Neue Herausforderung für die interdisziplinäre Zusammenarbeit

  2020influential citation
• Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study

  2020cites this paper
• SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges

  2020cites this paper
• Tumour mutational burden: a review

  2020influential citation
• SMARCA4 mutations in KRAS‐mutant lung adenocarcinoma: a multi‐cohort analysis

  2020cites this paper
• Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer

  2020cites this paper
• HIP1R Expression and Its Association with PD-1 Pathway Blockade Response in Refractory Advanced NonSmall Cell Lung Cancer: A Gene Set Enrichment Analysis

  2020cites this paper
• Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report

  2020cites this paper
• Bone Scintigraphy in Pembrolizumab-Induced Inflammatory Arthritis.

  2020cites this paper
• Pembrolizumab in the Treatment of Metastatic Non-Small Cell Lung Cancer

  2020cites this paper
• Raman Microspectroscopy for the Discrimination of Thyroid and Lung Cancer Subtypes for Application in Clinical Cytopathology

  2020cites this paper
• Institution-level differences in quality and outcomes of lung cancer resections in the United States.

  2020cites this paper
• Construction and Validation of a 7-Immune Gene Model for Prognostic Assessment of Esophageal Carcinoma

  2020cites this paper
• Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data

  2020cites this paper
• Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy

  2020cites this paper
• Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation

  2020cites this paper
• Role of Immunotherapy in Triple-Negative Breast Cancer.

  2020cites this paper
• A Case of Isolated Adrenocorticotropic Hormone Deficiency Caused by Pembrolizumab

  2020cites this paper
• Immune Checkpoints and Inhibitors

  2020cites this paper
• Signature based on immune-related LncRNA can predict overall survival of osteosarcoma patients

  2020cites this paper
• Rapidly Progressive Acute Kidney Injury Associated with Nivolumab Treatment

  2020cites this paper
• Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals.

  2020cites this paper
• Bombesin, endothelin, neurotensin and pituitary adenylate cyclase activating polypeptide cause tyrosine phosphorylation of receptor tyrosine kinases.

  2020cites this paper
• Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer

  2019cites this paper
• Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis

  2019cites this paper
• Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis

  2019cites this paper
• The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

  2019cites this paper
• Immunotherapy for skin cancer.

  2019cites this paper
• Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells

  2019cites this paper
• Bowel obstruction caused by colonic metastasis of lung adenocarcinoma: a case report and literature review

  2019cites this paper
• Efficacy of PD‐1/PD‐L1 inhibitors in patients with advanced non‐small cell lung cancer: A meta‐analysis of randomized clinical trials

  2019cites this paper
• Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

  2019cites this paper
• Role of tumor gene mutations in treatment response to immune checkpoint blockades

  2019cites this paper
• Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium

  2019cites this paper
• Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response

  2019cites this paper
• LINC00922 Accelerates the Proliferation, Migration and Invasion of Lung Cancer Via the miRNA-204/CXCR4 Axis

  2019cites this paper
• Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

  2019cites this paper
• PD-L 1 testing of non-small cell lung cancer using different antibodies and platforms : a Swiss cross-validation study

  2019cites this paper
• Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer

  2019cites this paper
• Tumour-intrinsic resistance to immune checkpoint blockade

  2019cites this paper
• Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.

  2019cites this paper
• Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner.

  2019cites this paper
• Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.

  2019cites this paper
• Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.

  2019influential citation
• Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment

  2019cites this paper
• Tumor mutational burden in lung cancer: a systematic literature review

  2019cites this paper
• Biomarkers that may predict response to immunotherapy in ovarian malignancies.

  2019cites this paper
• Brain immunology and immunotherapy in brain tumours

  2019cites this paper
• Mechanisms of immune evasion in bladder cancer

  2019cites this paper
• Salvage therapy of reactive capillary hemangiomas: Apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer

  2019cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

  2019cites this paper
• A Phase II Clinical Trial Design for Associated Co-primary Efficacy and Toxicity Outcomes with Baseline Covariates

  2018influential citation
• The lung microenvironment: an important regulator of tumour growth and metastasis

  2018cites this paper
• The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay

  2018cites this paper
• Predictive potential and need for standardization of PD-L1 immunohistochemistry

  2018cites this paper